Cyclacel Pharmaceuticals (CYCC) News Today $8.23 +0.03 (+0.37%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$8.12 -0.11 (-1.28%) As of 07/17/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYCC Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period CYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITYJuly 16 at 4:02 PM | finance.yahoo.comCyclacel stock dips after trimming 270% surge amid volatility concernsJuly 16 at 4:02 PM | msn.comWhy Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday?July 15 at 12:42 PM | benzinga.comWhy Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday?July 15 at 12:17 PM | benzinga.comCyclacel Pharmaceuticals, Inc. (CYCCP) - Yahoo FinanceJuly 13, 2025 | finance.yahoo.comCyclacel Pharmaceuticals (NASDAQ:CYCC) Upgraded by Wall Street Zen to "Hold" RatingJuly 12, 2025 | americanbankingnews.comCyclacel stock soars after amendment to exchange agreement with FITTERSJuly 7, 2025 | in.investing.comCyclacel Stock Surges 50% After Amending Exchange Agreement with FITTERSJuly 7, 2025 | msn.comCYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENTJuly 7, 2025 | globenewswire.comCYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCERJuly 7, 2025 | globenewswire.comCyclacel Pharmaceuticals Announces Stock Split - Seeking AlphaJuly 4, 2025 | seekingalpha.comCyclacel Pharmaceuticals Announces 1-for-15 Reverse Stock Split Effective July 7, 2025 - NasdaqJuly 4, 2025 | nasdaq.comCyclacel Pharmaceuticals announces 1-for-15 reverse stock splitJuly 3, 2025 | finance.yahoo.comCyclacel Pharmaceuticals Announces Stock SplitJuly 2, 2025 | globenewswire.comCyclacel (CYCC) Share News Today - Investing.com UKJuly 1, 2025 | uk.investing.comCYCC - Cyclacel Pharmaceuticals Inc Chart - MorningstarJune 27, 2025 | morningstar.comMCYCC - Cyclacel Pharmaceuticals Inc Ownership - MorningstarJune 27, 2025 | morningstar.comMCyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred StockJune 20, 2025 | globenewswire.comCYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENTJune 3, 2025 | globenewswire.comCyclacel Pharmaceuticals (NASDAQ:CYCC) Reaches New 1-Year Low - Here's WhyMay 16, 2025 | marketbeat.comCYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATEMay 14, 2025 | globenewswire.comCyclacel Pharmaceuticals (NASDAQ:CYCC) Shares Down 7.8% - Time to Sell?May 14, 2025 | marketbeat.comCyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by StockNews.comMay 12, 2025 | marketbeat.comCyclacel Pharmaceuticals (NASDAQ:CYCC) Shares Scheduled to Reverse Split on Monday, May 12thMay 10, 2025 | marketbeat.comCyclacel Pharmaceuticals, Inc.: Cyclacel Pharmaceuticals Announces Stock SplitMay 9, 2025 | finanznachrichten.deCYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLITMay 7, 2025 | globenewswire.comCYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN.May 6, 2025 | globenewswire.comCyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated by Analysts at StockNews.comMay 4, 2025 | marketbeat.comCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Short Interest UpdateApril 30, 2025 | marketbeat.comCyclacel Pharmaceuticals files to sell 35.18M shares of common stock for holdersApril 27, 2025 | markets.businessinsider.comCyclacel Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:CYCC | BenzingaApril 27, 2025 | benzinga.comCyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business UpdateApril 2, 2025 | globenewswire.comCyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred StockMarch 24, 2025 | globenewswire.comCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) CEO Sells $5,838,864.60 in StockMarch 1, 2025 | insidertrades.comCyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive LeadershipFebruary 27, 2025 | globenewswire.comCyclacel Pharmaceuticals adjusts shareholder rights, amends stockFebruary 12, 2025 | msn.comCyclacel stock plunges to 52-week low of $0.31 amid market challengesFebruary 11, 2025 | msn.comCyclacel Pharmaceuticals Restructures Leadership and Financial StrategyJanuary 7, 2025 | markets.businessinsider.comCyclacel announces agreement for acquisition of preferred stockJanuary 4, 2025 | markets.businessinsider.comDavid Lazar acquires Cyclacel Pharmaceuticals preferred stock, becomes interim CEO; stock jumpsJanuary 3, 2025 | msn.comCyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David LazarJanuary 3, 2025 | globenewswire.comCyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating CostsDecember 5, 2024 | globenewswire.comCyclacel Pharmaceuticals Reports Q3 2024 Financial ResultsNovember 19, 2024 | markets.businessinsider.comCyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross ProceedsNovember 14, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross ProceedsNovember 13, 2024 | globenewswire.comCyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business UpdateNovember 12, 2024 | globenewswire.comCyclacel Pharmaceuticals granted extension for regain Nasdaq complianceOctober 25, 2024 | markets.businessinsider.comCyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard RuleOctober 24, 2024 | globenewswire.comCyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR SymposiumOctober 23, 2024 | globenewswire.comCyclacel Pharmaceuticals (NASDAQ:CYCC) Stock, Insider Trading ActivityOctober 20, 2024 | benzinga.com Get Cyclacel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter. Email Address CYCC Media Mentions By Week CYCC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYCC News Sentiment▼0.120.97▲Average Medical News Sentiment CYCC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYCC Articles This Week▼231▲CYCC Articles Average Week Get Cyclacel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Relmada Therapeutics News Today Reviva Pharmaceuticals News Today VYNE Therapeutics News Today Cingulate News Today BioLineRx News Today MEI Pharma News Today Aytu BioPharma News Today Hoth Therapeutics News Today Carisma Therapeutics News Today Marker Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CYCC) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
